

Contact: Julie Miller
Phone: 310-437-0544, Ext. 179
Email: julie@sages.org



FOR IMMEDIATE RELEASE

The SINC Fund Has Made an Investment in Biotechnology Company MimiVax, Inc.

July 25, 2024 - Los Angeles, Calif. – The SINC Fund, a venture capital fund sponsored by SAGES Ingenuity Inc. (<https://www.sages-ingenuity.com>), a for-profit entity formed to invest in and accelerate innovation, and Varia Ventures Management Company, LLC (<https://www.varia.com>), a venture capital firm, are pleased to announce an investment in MimiVax, a clinical-stage biotech company that develops immunotherapeutics for cancer and autoimmune diseases.

“We are inspired by the trust the SINC fund has placed in MimiVax and their willingness to join us on our journey of providing more treatment options for glioblastoma patients,” said MimiVax Chief Executive Officer Michael Ciesielski, PhD. “Investments like those from the SINC fund allow us to include more patients in our trials and move our SurVaxM that much closer to approval.”

In May, the U.S. Food and Drug Administration awarded a supplemental orphan drug designation to MimiVax’s SurVaxM vaccine to include malignant glioma. The SurVaxM vaccine is currently being studied as a treatment for newly diagnosed glioblastoma (nGBM) in a phase 2b randomized clinical study (the SURVIVE trial) that will assess the efficacy of SurVaxM in a large patient population with nGBM. This supplemental orphan drug designation greatly expands the potential for SurVaxM’s use in other forms of pediatric and adult malignant gliomas. An orphan drug designation plays a critical role in encouraging the development of treatments for rare diseases, ultimately improving the lives of patients who might otherwise have few or no treatment options.

“The SINC Fund Investment Committee was impressed by the opportunity that this drug may bring to selected patients with glioblastoma multiforme. Early clinical trial results are encouraging, and we eagerly await the results of the pivotal trial.” said SD Schwaitzberg, MD, FACS, Chair of the SINC Fund Investment Committee.

The SINC Fund (<https://sincinvest.varia.com/>) was launched to give SAGES members and others the opportunity to invest in a venture fund with a portfolio of startups primarily in the therapeutic GI/GI surgery space. MimiVax, Inc is the third investment for the SINC Fund, with additional investments pending completion of due diligence. The SINC Fund is open to new investors only until September 1, 2024, when the fund will hold a final closing. If you are interested in learning more and potentially investing, please visit <https://www.varia.com/sinc>.

About SAGES

The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) is a leading surgical society representing a global community of more than 7,400 surgeons bringing minimal access surgery and emerging techniques to patients worldwide. SAGES' mission is to innovate, educate and collaborate to improve patient care with a vision of reimagining surgical care for a healthier world. For more information, go to <https://www.sages.org>.

About MimiVax, Inc

MimiVax, Inc. is a Delaware-incorporated, clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer treatment. MimiVax has conducted clinical trials to evaluate the safety and efficacy of SurVaxM in various types of cancer, including glioblastoma (a type of brain cancer), multiple myeloma, neuro-endocrine tumors (NET) and pediatric relapsed high grade glioma, medulloblastoma, ependymoma and diffuse intrinsic pontine glioma (DIPG). These trials have shown promising signs of immune response and potential clinical benefit. For more information on MimiVax, visit www.mimivax.com or email info@mimivax.com.

About SurVaxM

SurVaxM is an experimental cancer vaccine developed by MimiVax. It is designed to target a protein called survivin, which is found in many cancer cell types. Survivin plays a role in promoting cancer cell survival, tumor growth, and resistance to cell death. SurVaxM is delivered subcutaneously where it stimulates a patient's immune response against tumor cells with the intent to prevent future disease recurrence. While still in the experimental stages, SurVaxM holds potential as a new treatment option for patients with survivin-expressing forms of cancer.

Disclaimer:

None of SAGES, SAGES Ingenuity, Varia Ventures or any of their affiliates provides personalized advice about investments, and this content should not be construed or relied on as such. You should consult your own advisers concerning any investment. All content is for informational purposes only. This content does not constitute an offer to sell, or a solicitation of an offer to buy, an interest in any jurisdiction in which it unlawful to make such an offer or solicitation. Offers of securities are made only to accredited investors pursuant to a fund's offering documents, which describe the risks, fees and other information that should be considered before investing. This content may contain forward-looking statements, which should not be relied upon and are not guarantees of future results, performance, achievements or success. Certain information contained herein has been obtained from other parties. While such sources are believed to be reliable, none of SAGES, SAGES Ingenuity, Varia Ventures or any of their affiliates assumes any responsibility for the accuracy or completeness of such information. The information set forth herein does not purport to be complete and no obligation to update or otherwise revise such information is being assumed.